AIMS/HYPOTHESIS: Mitochondrial DNA (mtDNA) mutations cause several diseases, including mitochondrial inherited diabetes and deafness (MIDD), typically associated with the mtDNA A3243G point mutation on tRNALeu gene. The common hypothesis to explain the link between the genotype and the phenotype is that the mutation might impair mitochondrial metabolism expressly required for beta cell functions. However, this assumption has not yet been tested. METHODS: We used clonal osteosarcoma cytosolic hybrid cells (namely cybrids) harbouring mitochondria derived from MIDD patients and containing either exclusively wild-type or mutated (A3243G) mtDNA. According to the importance of mitochondrial metabolism in beta cells, we studied the impact of the mutation on key parameters by comparing stimulation of these cybrids by the main insulin secretagogue glucose and the mitochondrial substrate pyruvate. RESULTS: Compared with control mtDNA from the same patient, the A3243G mutation markedly modified metabolic pathways leading to a high glycolytic rate (2.8-fold increase), increased lactate production (2.5-fold), and reduced glucose oxidation (-83%). We also observed impaired NADH responses (-56%), negligible mitochondrial membrane potential, and reduced, only transient ATP generation. Moreover, cybrid cells carrying patient-derived mutant mtDNA exhibited deranged cell calcium handling with increased cytosolic loads (1.4-fold higher), and elevated reactive oxygen species (2.6-fold increase) under glucose deprivation. CONCLUSIONS/ INTERPRETATION: The present study demonstrates that the mtDNA A3243G mutation impairs crucial metabolic events required for proper cell functions, such as coupling of glucose recognition to insulin secretion.
AIMS/HYPOTHESIS: Mitochondrial DNA (mtDNA) mutations cause several diseases, including mitochondrial inherited diabetes and deafness (MIDD), typically associated with the mtDNA A3243G point mutation on tRNALeu gene. The common hypothesis to explain the link between the genotype and the phenotype is that the mutation might impair mitochondrial metabolism expressly required for beta cell functions. However, this assumption has not yet been tested. METHODS: We used clonal osteosarcoma cytosolic hybrid cells (namely cybrids) harbouring mitochondria derived from MIDD patients and containing either exclusively wild-type or mutated (A3243G) mtDNA. According to the importance of mitochondrial metabolism in beta cells, we studied the impact of the mutation on key parameters by comparing stimulation of these cybrids by the main insulin secretagogue glucose and the mitochondrial substrate pyruvate. RESULTS: Compared with control mtDNA from the same patient, the A3243G mutation markedly modified metabolic pathways leading to a high glycolytic rate (2.8-fold increase), increased lactate production (2.5-fold), and reduced glucose oxidation (-83%). We also observed impaired NADH responses (-56%), negligible mitochondrial membrane potential, and reduced, only transient ATP generation. Moreover, cybrid cells carrying patient-derived mutant mtDNA exhibited deranged cell calcium handling with increased cytosolic loads (1.4-fold higher), and elevated reactive oxygen species (2.6-fold increase) under glucose deprivation. CONCLUSIONS/ INTERPRETATION: The present study demonstrates that the mtDNA A3243G mutation impairs crucial metabolic events required for proper cell functions, such as coupling of glucose recognition to insulin secretion.
Authors: K Tsuruzoe; E Araki; N Furukawa; T Shirotani; K Matsumoto; K Kaneko; H Motoshima; K Yoshizato; A Shirakami; H Kishikawa; J Miyazaki; M Shichiri Journal: Diabetes Date: 1998-04 Impact factor: 9.461
Authors: J Antonie Maassen; Leen M 'T Hart; Einar Van Essen; Rob J Heine; Giel Nijpels; Roshan S Jahangir Tafrechi; Anton K Raap; George M C Janssen; Herman H P J Lemkes Journal: Diabetes Date: 2004-02 Impact factor: 9.461
Authors: Ning Li; Thierry Brun; Miriam Cnop; Daniel A Cunha; Decio L Eizirik; Pierre Maechler Journal: J Biol Chem Date: 2009-06-22 Impact factor: 5.157
Authors: Raymond Fox; Hyung-Suk Kim; Robert L Reddick; Gregory C Kujoth; Tomas A Prolla; Shuichi Tsutsumi; Youichiro Wada; Oliver Smithies; Nobuyo Maeda Journal: Proc Natl Acad Sci U S A Date: 2011-05-09 Impact factor: 11.205
Authors: Markus M Lindroos; Jussi P Pärkkä; Markku T Taittonen; Patricia Iozzo; Mikko Kärppä; Ilmo E Hassinen; Juhani Knuuti; Pirjo Nuutila; Kari Majamaa Journal: J Inherit Metab Dis Date: 2015-06-26 Impact factor: 4.982
Authors: F Frigerio; T Brun; C Bartley; A Usardi; D Bosco; K Ravnskjaer; S Mandrup; P Maechler Journal: Diabetologia Date: 2009-11-12 Impact factor: 10.122
Authors: Juan Garrido-Maraver; Mario D Cordero; Irene Domínguez Moñino; Sheila Pereira-Arenas; Ana V Lechuga-Vieco; David Cotán; Mario De la Mata; Manuel Oropesa-Ávila; Manuel De Miguel; Juan Bautista Lorite; Eloy Rivas Infante; Manuel Alvarez-Dolado; Plácido Navas; Sandra Jackson; Silvia Francisci; José A Sánchez-Alcázar Journal: Br J Pharmacol Date: 2012-11 Impact factor: 8.739